Cytosorbents Sets 2024 Annual Meeting Date

TL;DR

Cytosorbents (CTSO) holding annual shareholder meeting July 18th - vote on directors!

AI Summary

Cytosorbents Corporation announced on June 6, 2024, that it has scheduled its 2024 Annual Meeting of Stockholders for July 18, 2024. The meeting will include the election of directors and other business matters. The company is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing informs shareholders about the upcoming annual meeting where key corporate decisions, including director elections, will be made.

Risk Assessment

Risk Level: low — This is a routine corporate filing announcing a meeting date, with no immediate financial or operational risks disclosed.

Key Players & Entities

• Cytosorbents Corporation (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported
• July 18, 2024 (date) — Date of 2024 Annual Meeting of Stockholders
• Delaware (jurisdiction) — State of incorporation
• Princeton, New Jersey (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share CTSO The Nasdaq Stock Marke

Filing Documents

• tm2416630d1_8k.htm (8-K) — 39KB
• 0001104659-24-070039.txt ( ) — 208KB
• ctso-20240606.xsd (EX-101.SCH) — 3KB
• ctso-20240606_lab.xml (EX-101.LAB) — 33KB
• ctso-20240606_pre.xml (EX-101.PRE) — 22KB
• tm2416630d1_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders CytoSorbents Corporation (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 6, 2024. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1. The election of five (5) directors to serve until the Company's 2024 Annual Meeting of Stockholders, or until their respective successors shall have been duly elected and qualified; 2. The approval of, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K; 3. To approve an amendment (the "Plan Amendment") to the Amended and Restated CytoSorbents Corporation 2014 Long-term Incentive Plan (the "Plan"); and 4. The ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. At the close of business on April 12, 2024, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 54,306,415 shares of the Company's Common Stock outstanding and entitled to vote at the Annual Meeting. The holders of 40,028,453 shares of the Company's Common Stock were represented in person or by proxy at the Annual Meeting, constituting a quorum. At the Annual Meeting, (i) the five (5) directors were elected, (ii) the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K, was approved, on an advisory basis, (iii) the Plan Amendment was approved, and (iv) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. Proposal No. 1 — Election of Directors The vote with respect to the election of directors was as follows: Nominees For Against Abstain Broker Non-Votes Dr. Phillip P. Chan 26,614,052 2,331,387 300,946 10,782,068 Michael Bator

View Full Filing

View this 8-K filing on SEC EDGAR